CIA
VRTX icon

Capital Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$582K Buy
1,303
+132
+11% +$61.6K 0.01% 454
2025
Q4 		$531K Buy
1,171
+162
+16% +$69.8K 0.01% 472
2025
Q3 		$395K Buy
1,009
+12
+1% +$5.01K 0.01% 518
2025
Q2 		$444K Sell
997
-35
-3% -$16.1K 0.01% 474
2025
Q1 		$500K Buy
1,032
+190
+23% +$88.5K 0.01% 436
2024
Q4 		$339K Sell
842
-30
-3% -$13.9K 0.01% 494
2024
Q3 		$405K Buy
872
+37
+4% +$17.8K 0.01% 451
2024
Q2 		$391K Buy
835
+80
+11% +$34.7K 0.01% 442
2024
Q1 		$316K Sell
755
-81
-10% -$34.2K 0.01% 475
2023
Q4 		$340K Sell
836
-5
-0.6% -$1.85K 0.01% 445
2023
Q3 		$293K Buy
+841
New +$294K 0.01% 454
2022
Q3 		– Sell
-726
Closed -$205K – 574
2022
Q2 		$205K Buy
+726
New +$194K 0.01% 516
2022
Q1 		– Sell
-926
Closed -$203K – 619
2021
Q4 		$203K Buy
+926
New +$180K 0.01% 564

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Investment Advisors's VRTX Position: Q1 2026 in Review

Capital Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 11% in Q1 2026, buying an estimated $61.6K and bringing the position to 1,303 shares worth $582K. The position accounts for 0.01% of the portfolio, ranked #454.

Capital Investment Advisors first reported a position in VRTX in Q4 2021 and has held it in 13 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Capital Investment Advisors held 1,303 shares of Vertex Pharmaceuticals worth $582K as of Q1 2026.
  • Capital Investment Advisors bought 132 Vertex Pharmaceuticals shares in Q1 2026, an estimated $61.6K.
  • Vertex Pharmaceuticals made up 0.01% of Capital Investment Advisors's portfolio in Q1 2026, its #454 holding.
  • Capital Investment Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Capital Investment Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.